The incidence of occult metastasis (OM) in laryngeal squamous cell carcinoma (SCC) is still widely debated. In this systematic review, we aim to determine the rate of OM in laryngeal SCC, its impact on recurrence, and the role of elective neck dissection (END) in the management of the clinically negative neck.
Methods:
A systematic review of the English-language literature in Web of Science, PubMed, MEDLINE, and Cochrane Library databases on occult metastasis in laryngeal SCC from 1977 to 2018 was conducted. Studies evaluating occult metastasis (OM) in patients with laryngeal SCC with clinically negative necks undergoing surgery were included. Studies evaluating other head and neck subsites, clinically node positive, and salvage patients were excluded.
Results:
Twenty-one articles with a total of 5630 patients were included. The overall rate of OM was 20.5% and was 23% and 12.2% in supraglottic and glottic tumors, respectively. The OM rate in T1-T2 tumors was 13% and 25% in T3-T4 tumors. T3-T4 tumors had significantly greater odds of developing OM compared to T1-T2 tumors (Odds Ratio [OR] = 2.61, 95% Confidence Interval [CI] = 1.92-3.55, P < .00001). Patients with OM were more likely to develop distant metastasis (OR = 5.65, 95% CI = 3.36-9.51, P < .00001).
Conclusions:
Patients with advanced T-stage laryngeal SCC should undergo elective neck treatment. More aggressive treatment for patients with history of OM should be considered due to the risk of subsequent regional and distant metastasis.
MaHLianMFengL, et al. Factors contributing to lymph node occult metastasis in supraglottic laryngeal carcinoma cT2-T4 N0M0 and metastasis predictive equation. Chin J Cancer Res. 2014;26(6):685-691.
2.
CandelaFCShahJJaquesDPShahJP.Patterns of cervical node metastases from squamous carcinoma of the larynx. Arch Otolaryngol Head Neck Surg. 1990;116(4):432-435.
3.
GoudakosJKMarkouKNikolaouAThemelisCVitalV.Management of the clinically negative neck (N0) of supraglottic laryngeal carcinoma: a systematic review. Eur J Sug Oncol. 2009;35(3):223-229.
4.
ShahJP.Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg. 1990;160(4):405-409.
5.
YangCYAndersenPEEverysECCohenJI.Nodal disease in purely glottic carcinoma: is elective neck treatment worthwhile?Laryngoscope. 1998;108(7):1006-1008.
6.
ChiuRJMyersENJohnsonJT.Efficacy of routine bilateral neck dissection in the management of supraglottic cancer. Otolaryngol Head Neck Surg. 2004;131(4):485-488.
7.
MaHLianMFengL, et al. Management of cervical lymph nodes for cN0 advanced glottic laryngeal carcinoma and its long-term results. Acta Otolaryngol. 2014;134(9):952-958.
8.
BoccaECalearoCde VincentiisIMarulloTMottaGOttavianiA.Occult metastases in cancer of the larynx and their relationship to clinical and histological aspects of the primary tumor: a four-year multicentric research. Laryngoscope. 1984;94(8):1086-1090.
9.
GalloODeganelloAScalaJDe CamporaE.Evolution of elective neck dissection in N0 laryngeal cancer. Acta Otorhinolaryngol Ital. 2006;26(6):335-344.
10.
AlpertTEMorbidini-GaffneySChungCT, et al. Radiotherapy for the clinically negative neck in supraglottic laryngeal cancer. Cancer J. 2004;10(6):335-338.
11.
Brazilian Head and Neck Cancer Study Group. End results of a prospective trial on elective lateral neck dissection vs type III modified radical neck dissection in the management of supraglottic and transglottic carcinomas. Head Neck. 1999;21(8):694-702.
12.
MnejjaMHammamiBBougachaL, et al. Occult lymph node metastasis in laryngeal squamous cell carcinoma: therapeutic and prognostic impact. Eur Ann Otorhinolaryngol Head Neck Dis. 2010;127(5):173-176.
13.
MoherDLiberatiATetzlaffJAltmanDGPRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269.
14.
StangA.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605.
KligermanJOlivattoLOLimaRA, et al. Elective neck dissection in the treatment of T3/T4 N0 squamous cell carcinoma of the larynx. Am J Surg. 1995;170(5):436-439.
17.
PetrovicZKrejovicBJanosevicS.Occult metastases from supraglottic laryngeal carcinoma. Clin Otolaryngol. 1997;22(6):522-524.
18.
GuneyEYigitbasiOG.Management of N0 neck in T1-T2 unilateral supraglottic cancer. Ann Otol Rhinol Laryngol. 1999;108(10):998-1003.
19.
PinillaMGonzálezFMLópez-CortijoC, et al. Management of N0 neck in laryngeal carcinoma. Impact on patient’s survival. J Laryngol Otol. 2003;117(1):63-66.
20.
SprianoGPiantanidaRPelliniRMuscatelloL.Elective treatment of the neck in squamous cell carcinoma of the larynx: clinical experience. Head Neck. 2003;25(2):97-102.
21.
SarnoABoccioliniCDeganelloACoscarelliSGalloO.Does unnecessary elective neck treatment affect the prognosis of N0 laryngeal cancer patients?Acta Otolaryngol. 2004;124(8):980-985.
22.
RodrigoJPCabanillasRFrancoVSuarezC.Efficacy of routine bilateral neck dissection in the management of the N0 neck in T1-T2 unilateral supraglottic cancer. Head Neck. 2006;28(6):534-539.
23.
LimYCChoiECLeeJSKooBSSongMHShinHA.Is dissection of level IV absolutely necessary in elective lateral neck dissection for clinically N0 laryngeal carcinoma?Oral Oncol. 2006;42(1):102-107.
24.
CagliSYuceIYigitbasiOGGuneyE.Is routine bilateral neck dissection absolutely necessary in the management of N0 neck in patients with supraglottic carcinoma?Eur Arch Otorhinolaryngol. 2007;264(12):1453-1457.
25.
CagliSYuceIGuneyE.Is routine inclusion of level IV necessary in neck dissection for clinically N0 supraglottic carcinoma?Otolaryngol Head Neck Surg. 2007;136(2):287-290.
26.
DiasFLLimaRAManfroG, et al. Management of the N0 neck in moderately advanced squamous cell carcinoma of the larynx. Otolaryngol Head Neck Surg. 2009;141(1):59-65.
27.
YuceICagliSBayramAGuneyE.Occult metastases from T1-T2 supraglottic carcinoma: role of primary tumor localization. Eur Arch Otorhinolaryngol. 2009;266(8):1301-1304.
28.
DeganelloAGittiGMeccarielloGParrinelloGMannelliGGalloO.Effectiveness and pitfalls of elective neck dissection in N0 laryngeal cancer. Acta Otorhinolaryngol Ital. 2011;31(4):216-221.
29.
JiaSWangYHeHXiangC.Incidence of level IIB lymph node metastasis in supraglottic laryngeal squamous cell carcinoma with clinically negative neck–a prospective study. Head Neck. 2013;35(7):987-991.
30.
DjordjevicVBukurovBArsovicN, et al. Prospective case-control study of efficacy of bilateral selective neck dissection in primary surgical treatment of supraglottic laryngeal cancers with clinically negative cervical findings (N0). Clin Otolaryngol. 2016;41(6):634-639.
31.
Motiee LangroudiMAmirzargarBAmaliA, et al. Rate of occult cervical lymph node involvement in supraglottic squamous cell carcinoma. Iran J Otorhinolaryngol. 2017;29(92):133-136.
32.
GalloOBoddiVBottaiGVParrellaFStorchiOF.Treatment of the clinically negative neck in laryngeal cancer patients. Head Neck. 1996;18(6):566-572.
33.
LindbergR.Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 1972;29(6):1446-1449.
34.
ByersRMWolfPFBallantyneAJ.Rationale for elective modified neck dissection. Head Neck Surg. 1988;10(3):160-167.
35.
WongRJRinaldoAFerlitoAShahJP.Occult cervical metastasis in head and neck cancer and its impact on therapy. Acta Otolaryngol. 2002;122(1):107-114.
36.
SpiroRHGalloOShahJP. Selective jugular node dissection in patients with squamous carcinoma of the larynx or pharynx. Am J Surg. 1993;166(4):399-402.
37.
OzdekASaracSAkyolMUUnalOFSungurA.Histopathological predictors of occult lymph node metastases in supraglottic squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2000;257(7):389-392.
38.
DavidsonBJSpiroRHPatelSPatelKShahJP.Cervical metastases of occult origin: the impact of combined modality therapy. Am J Surg. 1994;168(5):395-399.
39.
MoeKWolfGTFisherSGHongWK.Regional metastases in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg. 1996;122(6):644-648.
40.
MyersENFaganJF.Management of the neck in cancer of the larynx. Ann Otol Rhinol Laryngol. 1999;108(9):828-832.
41.
FerlitoARinaldoAThomas RobbinsK, et al. Changing concepts in the surgical management of the cervical node metastasis. Oral Oncology. 2003;39(5):429-435.
42.
MatsuoJMPatelSGSinghB, et al. Clinical nodal stage is an independently significant predictor of distant failure in patients with squamous cell carcinoma of the larynx. Ann Surg. 2003;238(3):412-421; discussion 421-422.
43.
BernierJCooperJSPajakTF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843-850.
44.
MedinaJEFerlitoARobbinsKT, et al. Central compartment dissection in laryngeal cancer. Head Neck. 2011;33(5):746-752.
45.
SunRTangXYangYZhangC.(18)FDG-PET/CT for the detection of regional nodal metastasis in patients with head and neck cancer: a meta-analysis. Oral Oncol. 2015;51(4):314-320.
46.
DedivitisRAAiresFTCerneaCRBrandaoLG.Pharyn-gocutaneous fistula after total laryngectomy: systematic review of risk factors. Head Neck. 2015;37(11):1691-1697.
47.
BusoniMDeganelloAGalloO.Pharyngocutaneous fistula following total laryngectomy: analysis of risk factors, prognosis and treatment modalities. Acta Otorhinolaryngol Ital. 2015;35(6):400-405.
48.
LansaatLvan der NoortVBernardSE, et al. Predictive factors for pharyngocutaneous fistulization after total laryngectomy: a Dutch Head and Neck Society audit. Eur Arch Otorhinolaryngol. 2018;275(3):783-794.
49.
EasterbrookPJGopalanRBerlinJAMatthewsDR.Publication bias in clinical research. Lancet. 1991;337(8746):867-872.
50.
OrdingAGCronin-FentonDEhrensteinV, et al. Challenges in translating endpoints from trials to observational cohort studies in oncology. Clin Epidemiol. 2016;8:195-200.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
